13 citations
,
January 2024 in “Cadernos de Saúde Pública”
Many hospitalized COVID-19 patients still have symptoms like fatigue and hair loss up to a year later, especially older, lower-income individuals with other health issues.
One-third of COVID-19 patients had long-term symptoms like hair loss and fatigue, with women, older individuals, blood group B, smokers, and those with more virus exposure at higher risk.
A person with hair loss since COVID-19 is considering treatments like finasteride and minoxidil but is hesitant due to potential side effects. Suggestions include visiting a dermatologist, using a ketoconazole shampoo, and considering that post-COVID hair loss might be an autoimmune response.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
The post and conversation are about the use of oral Minoxidil (Min), Finasteride (Fin), and RU58841 for hair loss treatment, with mixed opinions on their safety and effectiveness.